{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:28:37Z","timestamp":1771561717728,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006281","name":"Aboca S.p.A. Societ\u00e0 Agricola","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006281","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Suspect screening and untargeted analysis using UHPLC-qToF are two advanced analytical approaches now used to achieve an extensive chemical profile of samples, which are then typically confirmed through targeted analysis. These techniques can detect a large number of chemical features simultaneously and are currently being introduced into the study of contaminants of emerging concern (CECs) and into the study of the extent of human chemical exposure (the exposome). Here is described the use of these techniques to characterize chemical mixtures derived from the OECD 301F ready biodegradability test (RBT) of a chemical and natural formulation currently used to treat reflux disease and functional dyspepsia. Untargeted analysis clearly evidenced a different behavior between formulations containing only natural products with respect to that containing synthetic and non-naturally occurring substances. Suspect screening analysis improved the untargeted analysis of the omeprazole-based medicine, leading to the tentative identification of a number of omeprazole-derived transformation products, thereby enabling their preliminary quali-quantitative evaluation. Targeted analysis was then performed to confirm the preliminary data gained from the suspect screening approach. The validation of the analytical method for the quantitative determination of omeprazole and its major metabolite, omeprazole sulphide, has provided robust data to evaluate the behavior of omeprazole during the OECD 301F test. Using advanced analytical approaches, the RBT performed on the two products under investigation confirmed that omeprazole is not readily biodegradable, while the medical device made of natural substances has proven to be readily biodegradable.<\/jats:p>","DOI":"10.1038\/s41598-023-49948-8","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:02:14Z","timestamp":1704189734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Suspect screening analysis to improve untargeted and targeted UHPLC-qToF approaches: the biodegradability of a proton pump inhibitor medicine and a natural medical device"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5566-8919","authenticated-orcid":false,"given":"Luisa","family":"Mattoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Fodaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio Marzio","family":"Quintiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6243-9073","authenticated-orcid":false,"given":"Michela","family":"Burico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2955-8240","authenticated-orcid":false,"given":"Mattia","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Giovagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Mercati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Santi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"49948_CR1","unstructured":"Regulation (EC) No 2006\/1907 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency."},{"key":"49948_CR2","unstructured":"Regulation (EC) No 2012\/528 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products."},{"key":"49948_CR3","unstructured":"Directive (EC) No 2001\/83 of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use."},{"key":"49948_CR4","unstructured":"Regulation (EC) No 2019\/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001\/82\/EC."},{"key":"49948_CR5","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1021\/acs.est.6b05717","volume":"51","author":"TJ Martin","year":"2017","unstructured":"Martin, T. J. et al. Environmentally relevant inoculum concentrations improve the reliability of persistent assessments in biodegradation screening tests. Environ. Sci. Technol. 51, 3065\u20133073 (2017).","journal-title":"Environ. Sci. Technol."},{"key":"49948_CR6","doi-asserted-by":"publisher","DOI":"10.1787\/9789264030213-en","volume-title":"Revised introduction to the OECD guidelines for testing of chemicals, Section 3","author":"OECD","year":"2006","unstructured":"OECD. Revised introduction to the OECD guidelines for testing of chemicals, Section 3 (OECD, 2006)."},{"key":"49948_CR7","unstructured":"OECD, Test No. 301: Ready Biodegradability (1992)"},{"key":"49948_CR8","unstructured":"OECD, Test No. 310: Ready Biodegradability\u2014CO2 in sealed vessels (Headspace Test) (2006)."},{"key":"49948_CR9","doi-asserted-by":"publisher","unstructured":"Biodegradation. IUPAC. Compendium of Chemical Terminology, 2nd ed, in McNaught, A. D., & Wilkinson. A. (Blackwell Scientific Publications, 1997). Online version (2019-) created by S. J. Chalk. . https:\/\/doi.org\/10.1351\/goldbook.","DOI":"10.1351\/goldbook"},{"key":"49948_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ecoenv.2014.09.021","volume":"111","author":"A Kowalczyk","year":"2015","unstructured":"Kowalczyk, A. et al. Refinement of biodegradation tests methodologies and the proposed utility of new microbial ecology techniques. Ecotoxicol. Environ. Saf. 111, 9\u201322 (2015).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"49948_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1039\/D1VA00038A","volume":"1","author":"L Mattoli","year":"2022","unstructured":"Mattoli, L. et al. New insight into the evaluation of complex mixtures biodegradability. UHPLC-qToF \u201call-ion MS\/MS\u201d acquisition technique for the untargeted and targeted analysis of pharmaceutical formulations biodegradation. Environ. Sci. Adv. 1, 725\u2013735 (2022).","journal-title":"Environ. Sci. Adv."},{"key":"49948_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jms.4924","author":"G Proietti","year":"2023","unstructured":"Proietti, G. et al. Ready biodegradability study and insights with UHPLC-qToF of a Metformin-based drug and of Metarecod, a natural substance-based medical device. Mass Spect. https:\/\/doi.org\/10.1002\/jms.4924 (2023).","journal-title":"Mass Spect."},{"key":"49948_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1039\/D1AY00111F","volume":"13","author":"B Gonz\u00e1lez-Gaya","year":"2021","unstructured":"Gonz\u00e1lez-Gaya, B. et al. Suspect and non-target screening: The last frontier in environmental analysis. Anal. Methods 13, 1876\u20131904 (2021).","journal-title":"Anal. Methods"},{"key":"49948_CR14","doi-asserted-by":"publisher","first-page":"105545","DOI":"10.1016\/j.envint.2020.105545","volume":"139","author":"M Pourchet","year":"2020","unstructured":"Pourchet, M. et al. Suspect and non-targeted screening of chemicals of emerging concern for human biomonitoring, environmental health studies and support to risk assessment: From promises to challenges and harmonisation issues. Environ. Int. 139, 105545 (2020).","journal-title":"Environ. Int."},{"key":"49948_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.envint.2016.11.026","volume":"100","author":"SS Andra","year":"2017","unstructured":"Andra, S. S. et al. Trends in the application of high-resolution mass spectrometry for human biomonitoring: An analytical primer to studying the environmental chemical space of the human exposome. Environ. Int. 100, 32\u201361 (2017).","journal-title":"Environ. Int."},{"key":"49948_CR16","unstructured":"ECHA-SID (2017). Identification and naming of substances under REACH and CLP. Guidance ECHA-17-G-08-EN. Version 2.1."},{"key":"49948_CR17","unstructured":"Agilent Technologies, \u00abAll Ions MS\/MS: Targeted Screening and Quantitation Using Agilent TOF and Q-TOF LC\/MS Systems.,\u00bb Application note 5991\u20132465EN (2013)."},{"key":"49948_CR18","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1021\/acs.analchem.7b00925","volume":"89","author":"S Naz","year":"2017","unstructured":"Naz, S. et al. Development of a liquid chromatography-high resolution mass spectrometry metabolomics method with high specificity for metabolite identification using all ion fragmentation acquisition. Anal. Chem. 89, 7933 (2017).","journal-title":"Anal. Chem."},{"key":"49948_CR19","first-page":"11","volume":"12","author":"L Mattoli","year":"2014","unstructured":"Mattoli, L. et al. A hypothesis on peculiar pharmacological behaviour of biologically active natural compounds. Curr. Top. Phytochem. 12, 11\u201319 (2014).","journal-title":"Curr. Top. Phytochem."},{"key":"49948_CR20","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002360","author":"ES Corazziari","year":"2023","unstructured":"Corazziari, E. S. et al. Poliprotect vs Omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions: A randomized, controlled trial. Am. J. Gastroenterol. https:\/\/doi.org\/10.14309\/ajg.0000000000002360 (2023).","journal-title":"Am. J. Gastroenterol."},{"key":"49948_CR21","unstructured":"ECHA, \u00abGuidance on Information Requirements and Chemical Safety Assessment. Chapter R.7b: Endpoint specific guidance. Version 4.0,\u00bb ECHA-17-G-10-EN (2017)."},{"key":"49948_CR22","unstructured":"Council regulation (EC) No 440\/2008 laying down test methods in accordance to Regulation (EC) No 1907\/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)."},{"key":"49948_CR23","unstructured":"IVL Swedish Environmental Research Institute Commissioned Report, \u00abInvestigation of the \u2018ready biodegradability\u2019 of A001 drug substance,,\u00bb Report BD3984 (1991)."},{"key":"49948_CR24","unstructured":"FDA, \u00abPrilosec (omeprazole) for Delayed-Release Oral Suspension. Environmental assessment.,\u00bb (2008). Accessed 5 May 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022056_prilosec_toc.cfm."},{"key":"49948_CR25","unstructured":"ECHA, \u00abBiodegradation in water: screening tests. 1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1). Accessed 4 May 2023, https:\/\/echa.europa.eu\/it\/registration-dossier\/-\/registered-dossier\/27361\/5\/3\/2."},{"key":"49948_CR26","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1002\/jssc.201100540","volume":"34","author":"F Hern\u00e1ndez","year":"2011","unstructured":"Hern\u00e1ndez, F., Ib\u00e1\u00f1ez, M., Gracia-Lor, E. & Sancho, J. Retrospective LC-QTOF-MS analysis searching for pharmaceutical metabolites in urban wastewater. J. Sep. Sci. 34, 3517\u20133526 (2011).","journal-title":"J. Sep. Sci."},{"key":"49948_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/00365528509095821","volume":"20","author":"C-G Reg\u00e5rdh","year":"1985","unstructured":"Reg\u00e5rdh, C.-G., Gabrielsson, M., Hoffman, K.-J., L\u00f6fberg, I. & Sk\u00e5nberg, I. Pharmacokinetics and metabolism of omeprazole in animals and man\u2014an overview. Scand. J. Gastroenterol. 20, 79\u201394 (1985).","journal-title":"Scand. J. Gastroenterol."},{"key":"49948_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.scitotenv.2016.06.160","volume":"1569\u2013570","author":"C Kosma","year":"2016","unstructured":"Kosma, C., Lambropoulou, D. & Albanis, T. Analysis, occurrence, fate and risks of proton pump inhibitors, their metabolites and transformation products in aquatic environment: A review. Sci. Total Environ. 1569\u2013570, 732\u2013750 (2016).","journal-title":"Sci. Total Environ."},{"key":"49948_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11306-007-0081-3","volume":"3","author":"R Goodacre","year":"2007","unstructured":"Goodacre, R. et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 3, 231\u2013241 (2007).","journal-title":"Metabolomics"},{"key":"49948_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/mas.21773","volume":"42","author":"L Mattoli","year":"2023","unstructured":"Mattoli, L., Gianni, M. & Burico, M. Mass spectrometry-based metabolomic analysis as a tool for quality control of natural complex products. Mass Spectrom. Rev. 42, 1358\u20131396 (2023).","journal-title":"Mass Spectrom. Rev."},{"key":"49948_CR31","unstructured":"Guideline on the environmental risk assessment of medicinal products for human use\u2014EMEA\/CHMP\/SWP\/4447\/00 Corr 2 (2006)."},{"key":"49948_CR32","unstructured":"Guideline on the environmental risk assessment of medicinal products for human use\u2014EMEA\/CHMP\/SWP\/4447\/00 Rev 1 (2018)."},{"key":"49948_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","volume":"3","author":"LW Sumner","year":"2007","unstructured":"Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics 3, 211\u2013221 (2007).","journal-title":"Metabolomics"},{"key":"49948_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/es5002105","volume":"48","author":"EL Schymanski","year":"2014","unstructured":"Schymanski, E. L. et al. Identifying small molecules via high resolution mass spectrometry: Communicating confidence. Environ. Sci. Technol. 48, 2097\u20132098 (2014).","journal-title":"Environ. Sci. Technol."},{"key":"49948_CR35","unstructured":"M. Barrow, \u00abMass calculations: mass error and m\/z from formula,\u00bb Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV4 7AL. Accessed 17 June 2023. https:\/\/warwick.ac.uk\/fac\/sci\/chemistry\/research\/barrow\/barrowgroup\/calculators\/mass_errors\/."},{"key":"49948_CR36","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.scitotenv.2017.02.233","volume":"590\u2013591","author":"CI Kosma","year":"2017","unstructured":"Kosma, C. I., Lambropoulou, D. A. & Albanis, T. A. Photochemical transformation and wastewater fate and occurrence of omeprazole: HRMS for elucidation of transformation products and target and suspect screening analysis in wastewaters. Sci. Total Environ. 590\u2013591, 592\u2013601 (2017).","journal-title":"Sci. Total Environ."},{"key":"49948_CR37","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1039\/C9NJ00932A","volume":"43","author":"G Shankar","year":"2019","unstructured":"Shankar, G. et al. Identification and structural characterization of the stress degradation products of omeprazole using Q-TOF-LC-ESI-MS\/MS and NMR experiments: Evaluation of the toxicity of the degradation products. N. J. Chem. 43, 7294 (2019).","journal-title":"N. J. Chem."},{"key":"49948_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.scitotenv.2013.08.095","volume":"468\u2013469","author":"C Boix","year":"2014","unstructured":"Boix, C. et al. Identification of new omeprazole metabolites in wastewaters and surface waters. Sci. Total Environ. 468\u2013469, 706\u2013714 (2014).","journal-title":"Sci. Total Environ."},{"key":"49948_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhazmat.2015.09.059","volume":"302","author":"C Boix","year":"2016","unstructured":"Boix, C. et al. High resolution mass spectrometry to investigate omeprazole and venlafaxine metabolites in wastewater. J. Hazard. Mater. 302, 332\u2013340 (2016).","journal-title":"J. Hazard. Mater."},{"issue":"7","key":"49948_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/life10070115","volume":"10","author":"S-H Shin","year":"2020","unstructured":"Shin, S.-H. et al. Profiling and identification of omeprazole metabolites in mouse brain and plasma by isotope ratio-monitoring liquid chromatography-mass spectrometric method. Life 10(7), 115 (2020).","journal-title":"Life"},{"key":"49948_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003088-200140060-00003","volume":"40","author":"T Andersson","year":"2001","unstructured":"Andersson, T., Hassan-Alin, M., Hasselgren, G., R\u00f6hss, K. & Weidolf, L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 40, 411\u2013426 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"49948_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chroma.2008.10.122","volume":"1215","author":"A Petsalo","year":"2008","unstructured":"Petsalo, A., Turpeinen, M., Pelkonen, O. & Tolonen, A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography tandem mass spectrometry utilizing sub 2 \u00b5m particle size column. J. Chromatogr. A 1215, 107\u2013115 (2008).","journal-title":"J. Chromatogr. A"},{"key":"49948_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jms.3260","volume":"48","author":"C Boix","year":"2013","unstructured":"Boix, C., Ib\u00e1\u00f1ez, M., Sancho, J. V., Niessen, W. M. & Hern\u00e1ndez, F. Investigating the presence of omeprazole in waters by liquid chromatography coupled to low and high resolution mass spectrometry: degradation experiments. J. Mass Spectrom. 48, 1091\u20131100 (2013).","journal-title":"J. Mass Spectrom."},{"key":"49948_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12302-023-00779-4","volume":"35","author":"J Hollender","year":"2023","unstructured":"Hollender, J. et al. NORMAN guidance on suspect and non-target screening in environmental monitoring. Environ. Sci. Eur. 35, 75 (2023).","journal-title":"Environ. Sci. Eur."},{"key":"49948_CR45","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1038\/s41598-020-62573-z","volume":"10","author":"J Liigand","year":"2020","unstructured":"Liigand, J. et al. Quantification for non-targeted LC\/MS screening without standard substances. Sci. Rep. 10, 5808 (2020).","journal-title":"Sci. Rep."}],"updated-by":[{"DOI":"10.1038\/s41598-024-53924-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49948-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:18:01Z","timestamp":1709831881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49948-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["49948"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-49948-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-53924-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-53924-1","URL":"https:\/\/doi.org\/10.1038\/s41598-024-53924-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors listed below report the following details of affiliation or involvement in an organization or entity with a financial interest in the subject matter or materials discussed in this manuscript. LM, GP, GF, CMQ, GF, MB, GM are employed in Aboca who produce and commercialize the product indicated in the manuscript as B. VM is Honorary President of Aboca SPA. CS is the scientific responsible of a project related to the topic of the present manuscript and committed by Aboca to C.E.M.I.N (UniPG). Product A is a generic drug containing Omeprazole, while \u201cProduct B\u201d, Neobianacid, is a Medical device made of substances. Both products are indicated for the treatment reflux diseases and functional dyspepsia.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}